Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV

Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV Purpose of reviewTo summarize the state-of-the-art literature on the epidemiology, disease progression, and mediators of heart failure, tachyarrhythmias, and sudden cardiac death in people living with HIV (PLWH) to inform prevention strategies.Recent findingsRecent studies corroborate the role of HIV as a risk enhancer for heart failure and arrhythmias, which persists despite adjustment for cardiovascular risk factors and unhealthy behaviors. Immune activation and inflammation contribute to the risk. Heart failure occurs more frequently at younger ages, and among women and ethnic minorities living with HIV, highlighting disparities. Prospective outcome studies remain sparse in PLWH limiting prevention approaches. However, subclinical cardiac and electrophysiologic remodeling and dysfunction detected by noninvasive testing are powerful disease surrogates that inform our mechanistic understanding of HIV-associated cardiovascular disease and offer opportunities for early diagnosis.SummaryAggressive control of HIV viremia and cardiac risk factors and abstinence from unhealthy behaviors remain treatment pillars to prevent heart failure and arrhythmic complications. The excess risk among PLWH warrants heightened vigilance for heart failure and arrhythmic symptomatology and earlier testing as subclinical abnormalities are common. Future research needs include identifying novel therapeutic targets to prevent heart failure and arrhythmias and testing of interventions in diverse groups of PLWH. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/prevention-of-heart-failure-tachyarrhythmias-and-sudden-cardiac-death-IY1XWtA0XN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/coh.0000000000000753
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewTo summarize the state-of-the-art literature on the epidemiology, disease progression, and mediators of heart failure, tachyarrhythmias, and sudden cardiac death in people living with HIV (PLWH) to inform prevention strategies.Recent findingsRecent studies corroborate the role of HIV as a risk enhancer for heart failure and arrhythmias, which persists despite adjustment for cardiovascular risk factors and unhealthy behaviors. Immune activation and inflammation contribute to the risk. Heart failure occurs more frequently at younger ages, and among women and ethnic minorities living with HIV, highlighting disparities. Prospective outcome studies remain sparse in PLWH limiting prevention approaches. However, subclinical cardiac and electrophysiologic remodeling and dysfunction detected by noninvasive testing are powerful disease surrogates that inform our mechanistic understanding of HIV-associated cardiovascular disease and offer opportunities for early diagnosis.SummaryAggressive control of HIV viremia and cardiac risk factors and abstinence from unhealthy behaviors remain treatment pillars to prevent heart failure and arrhythmic complications. The excess risk among PLWH warrants heightened vigilance for heart failure and arrhythmic symptomatology and earlier testing as subclinical abnormalities are common. Future research needs include identifying novel therapeutic targets to prevent heart failure and arrhythmias and testing of interventions in diverse groups of PLWH.

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Sep 16, 2022

References

  • Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV
  • Assessing cardiovascular risk in people living with HIV: current tools and limitations
  • Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities
  • Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study
  • Adjudicated heart failure in HIV-infected and uninfected men and women
  • Human immunodeficiency virus infection and incident heart failure: a meta-analysis of prospective studies
  • Human immunodeficiency virus infection and variation in heart failure risk by age, sex, and ethnicity: the HIV HEART study
  • HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database
  • Human immunodeficiency virus increases the risk of incident heart failure
  • Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis
  • Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association
  • Differential associations of chronic inflammatory diseases with incident heart failure
  • Age at diagnosis of heart failure in united states veterans with and without HIV infection
  • Heart failure outcomes and associated factors among veterans with human immunodeficiency virus infection
  • Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center
  • Human immunodeficiency virus infection and risk of heart failure rehospitalizations
  • Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure
  • Long-term trajectories of left ventricular ejection fraction in patients with chronic inflammatory diseases and heart failure: an analysis of electronic health records
  • Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
  • Associations between HIV serostatus and cardiac structure and function evaluated by 2-dimensional echocardiography in the multicenter AIDS cohort study
  • Assessment of left ventricular function by echocardiography: the case for routinely adding global longitudinal strain to ejection fraction
  • Global longitudinal strain and immune status in patients living with human immunodeficiency virus
  • HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans
  • Cardiac magnetic resonance reveals signs of subclinical myocardial inflammation in asymptomatic HIV-infected patients
  • Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients
  • HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema
  • Cardiac involvement in human immunodeficiency virus infected patients: an observational cardiac magnetic resonance study
  • Diastolic dysfunction in patients with human immunodeficiency virus receiving antiretroviral therapy: results from the CHART Study
  • Determinants of left ventricular hypertrophy and diastolic dysfunction in an HIV clinical cohort
  • Recommendations for the evaluation of left ventricular diastolic function by echocardiography
  • Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
  • Diastolic dysfunction in people with HIV without known cardiovascular risk factors in Western Kenya
  • Echocardiographic findings in a cohort of perinatally hiv-infected adolescents compared with uninfected peers from the Cape Town adolescent antiretroviral cohort
  • Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals
  • Sex, HIV status, and measures of cardiac stress and fibrosis in Uganda
  • Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults
  • Human immunodeficiency viral infection and differences in interstitial ventricular fibrosis and left atrial size
  • Myocardial fibrosis and inflammation by CMR predict cardiovascular outcome in people living with HIV
  • Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults
  • Myocardial steatosis among antiretroviral therapy-treated people with human immunodeficiency virus participating in the REPRIEVE trial
  • Transmethylamine-N-oxide is associated with diffuse cardiac fibrosis in people living with HIV
  • Progression of cardiac structure and function in people with human immunodeficiency virus
  • HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women
  • Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity
  • Atrial arrhythmia prevalence and characteristics for human immunodeficiency virus-infected persons and matched uninfected controls
  • Association between human immunodeficiency virus serostatus and the prevalence of atrial fibrillation
  • Human immunodeficiency virus infection and incident atrial fibrillation
  • Risk factors for atrial fibrillation in a multi-center US clinical cohort of people with HIV infection
  • Prevalence and associated stroke risk of human immunodeficiency virus-infected patients with atrial fibrillation- a nationwide cohort study
  • Cardiac magnetic resonance-measured left atrial volume and function and incident atrial fibrillation: results from MESA (multi-ethnic study of atherosclerosis)
  • Sudden cardiac death in patients with human immunodeficiency virus infection
  • HIV infection and the risk of World Health Organization-defined sudden cardiac death
  • Human immunodeficiency virus infection and out-of-hospital cardiac arrest
  • The risk for sudden cardiac death among patients living with heart failure and human immunodeficiency virus
  • Incidence, predictors, and outcomes of implantable cardioverter-defibrillator discharge among people living with HIV
  • Sudden cardiac death and myocardial fibrosis, determined by autopsy, in persons with HIV
  • Sudden cardiac death risk stratification
  • HIV-Tat induces a decrease in IKr and IKsvia reduction in phosphatidylinositol-(4,5)-bisphosphate availability
  • Blockade of HERG channels by HIV protease inhibitors
  • HIV and nonischemic heart disease
  • The impact of opioids on cardiac electrophysiology
  • Prolongation of the QTc interval in HIV-infected individuals compared to the general population
  • Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study
  • Predictors of electrocardiographic QT interval prolongation in men with HIV
  • Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors
  • Prevalence and correlates of electrocardiographic abnormalities in adults with HIV: insights from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
  • Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV
  • Associations between QT interval subcomponents, HIV serostatus, and inflammation
  • Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa
  • Association between exposure to Efavirenz and substrates of dysrhythmia in HIV-infected young adults
  • De novo electrocardiographic abnormalities in persons living with HIV
  • Association between temporal changes in early repolarization pattern with long-term cardiovascular outcome: a population-based cohort study
  • ECG left ventricular hypertrophy as a risk predictor of sudden cardiac death
  • QT interval variability in body surface ECG: measurement, physiological basis, and clinical value: position statement and consensus guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group on Cardiac Cellular Electrophysiology
  • Current assessment of heart rate variability and QTc interval length in HIV/AIDS
  • A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy
  • HIV infection is associated with variability in ventricular repolarization: the multicenter AIDS cohort study (MACS)
  • Ventricular ectopy and arrhythmia characteristics for persons living with HIV and uninfected controls
  • Ventricular ectopy and arrhythmia by HIV serostatus, viremia, and CD4+ cell count